| P/E (FY) | 46.1 | Sales (TTM) | JPY 2.47T |
| Earnings (TTM) | JPY 363.15B | ROE | 12.59% |
| Net Margin | 14.71% | ROIC | 14.60% |
| Debt / Equity | 0.04 | TD / EBITDA | 0.21 |
| EPS Growth 3Y | 40.54% | Sales Growth 3Y | 12.41% |
Otsuka Holdings operates pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceuticals in psychiatry, neurology, oncology, cardiovascular and renal, autoimmune, digestive, and ophthalmology areas, along with diagnostics, intravenous solutions, and medical devices. The company also provides clinical testing, medical equipment, food products, cosmetics, functional foods, chemicals, soft drinks, nutritional products, IT solutions, and various molded resin and packaging products.
| Market Cap | $37.77B | Trading Days | 3788 |
| 52W High | 11910.00 |
| 52W Low | 7040.00 |
| % Off High | −4.41% |
| YTD | 29.14% | 1Y | 60.30% |
| 3Y | 119.80% | 5Y | 176.38% |
| 10Y | 189.30% | Since incept. (ann.) | 13.68% |
| Ann. Volatility (1Y) | 31.18% | Ann. Volatility (3Y) | 30.55% |
| Sharpe (1Y) | 1.79 | Sharpe (3Y) | 1.12 |
| Max Drawdown (1Y) | −12.93% | Max Drawdown (3Y) | −30.98% |
| Beta (3Y, vs SPY) | 0.06 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $38.01B | 123.0 |
| WAT | WATERS CORP /DE/ | $37.26B | 35.3 |
| RVMD | Revolution Medicines, Inc. | $38.46B | — |
| NTRA | Natera, Inc. | $36.35B | — |
| A | AGILENT TECHNOLOGIES, INC. | $39.63B | 30.7 |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $40.45B | 28.7 |
| AGL | agilon health, inc. | $41.04B | — |
| IQV | IQVIA HOLDINGS INC. | $41.32B | 31.6 |
| 4568.T | DAIICHI SANKYO COMPANY, LIMITED | $33.44B | 20.6 |
| RPRX | Royalty Pharma plc | $33.40B | 33.2 |
| MDLN | Medline Inc. | $32.81B | — |
| GEHC | GE HealthCare Technologies Inc. |
| $32.71B |
| 15.8 |
